XiaoningSun

Associate

シンガポール + 65.6233.5500

Connect:

共有

Xiaoning Sun represents financial institutions and sponsors/borrowers on a broad range of domestic and cross-border debt transactions, including club and syndicated loans; project, acquisition, and asset financings; and debt restructurings.

Prior to joining Jones Day in 2023, Xiaoning practiced at a top-tier international law firm in Singapore where she advised clients on a range of debt-related transactions, including project financing, asset financing, and capital call financing.

担当案件

  • Coronado Global Resources completes $400 million Senior Secured Notes offeringJones Day advised Coronado Global Resources Inc. (ASX: CRN) (“Coronado”), a global producer, marketer, and exporter of a full range of metallurgical coal products, in connection with an offering by one of its wholly-owned subsidiaries of US$400 million aggregate principal amount of 9.250% Senior Secured Notes due 2029 in a Rule 144A and Regulation S offering.
  • Five9 acquires AcqueonJones Day advised Five9, Inc. in its acquisition of Acqueon, a pioneering real-time revenue execution platform, realizing Five9's ambition to become the orchestration engine for every interaction across the entire customer journey, including marketing, e-commerce, sales and customer service through AI-driven, omnichannel proactive customer engagement.
  • Mayur Resources obtains US$155 million financing to complete Central Lime ProjectJones Day advised Mayur Resources Limited on the debt financing agreements with Appian Capital Advisory LLP and combined equity funding from Vision Blue Resources, a clean energy battery metals transition investment vehicle led by Sir Mick Davis, for a total of approximately US$155 million to complete the Central Lime Project.
  • Timken acquires Des-CaseJones Day advised The Timken Company in the acquisition of Des-Case Corp., a Nashville, Tenn.-based manufacturer of specialty filtration products for industrial lubricants.
  • Junshi grants exclusive rights to Dr. Reddy's for toripalimab cancer treatmentJones Day represented Shanghai Junshi Biosciences Co., Ltd. ("Junshi") in its grant of exclusive rights related to the development and commercialization of toripalimab, an anti-PD1 monoclonal antibody, to Dr. Reddy's Laboratories for the territory of Latin America, India, South Africa, and an option to expand the territory to include Australia and New Zealand and potential other countries.
    •

    July 2024 White Paper

    APAC ESG Update | Spring Quarter 2024

    February 2024 White Paper

    APAC ESG Update | Winter Quarter 2023–24

    送信する前の注意事項：

    www.jonesday.comに掲載されている情報は、一般的な使用を目的としており、法的アドバイスを目的としたものではありません。このEmailを送信することにより、弁護士を含む専門家・依頼者の関係を構築することを意図するものではなく、このEmailの受領はそのような関係を構築するものではありません。当事務所に送信されたいかなる情報も、業務委託契約を結ばない限り、弁護士等が依頼者に対して守秘義務を負う機密事項として取り扱われることはありません。このEmailの送信者は以上の注意事項の内容を読み、理解したものと判断します。